13,14-dihydroprostaglandin e1 has been researched along with 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid in 1 studies
| Studies (13,14-dihydroprostaglandin e1) | Trials (13,14-dihydroprostaglandin e1) | Recent Studies (post-2010) (13,14-dihydroprostaglandin e1) | Studies (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Trials (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) | Recent Studies (post-2010) (7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid) |
|---|---|---|---|---|---|
| 27 | 2 | 3 | 39 | 15 | 14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cawello, W; Schweer, H; Seyberth, HW | 1 |
1 other study(ies) available for 13,14-dihydroprostaglandin e1 and 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid
| Article | Year |
|---|---|
Gas chromatography/negative ion chemical ionization triple quadrupole mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid in plasma.
Topics: Adolescent; Adult; Alprostadil; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Prostaglandins | 1994 |